CTLA4 and hematologic disorder: The pooled results indicated that CTLA-4 49A/G polymorphism was associated with hematologic malignancy risk under dominant model (AA vs. GA+GG: OR = 1.77, 95% CI = 1.56-2.02, P = 0.001) (Figure 2).